Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone760-804-1648
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.26 million
Profitability
Miscellaneous
Employees95
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
RA Medical Systems (NYSE:RMED) Frequently Asked Questions
What is RA Medical Systems' stock symbol?
RA Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."
When is RA Medical Systems' next earnings date?
What guidance has RA Medical Systems issued on next quarter's earnings?
RA Medical Systems issued an update on its second quarter 2019 earnings guidance on Monday, August, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.02-2.2 million, compared to the consensus revenue estimate of $3.7 million.
What price target have analysts set for RMED?
4 brokerages have issued 12 month price objectives for RA Medical Systems' stock. Their predictions range from $1.50 to $12.00. On average, they expect RA Medical Systems' stock price to reach $6.38 in the next year. This suggests a possible upside of 368.8% from the stock's current price. View Analyst Price Targets for RA Medical Systems.
What is the consensus analysts' recommendation for RA Medical Systems?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RA Medical Systems in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RA Medical Systems.
Has RA Medical Systems been receiving favorable news coverage?
News coverage about RMED stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. RA Medical Systems earned a coverage optimism score of -4.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for RA Medical Systems.
Are investors shorting RA Medical Systems?
RA Medical Systems saw a decrease in short interest in September. As of September 30th, there was short interest totalling 187,300 shares, a decrease of 42.4% from the August 30th total of 325,400 shares. Based on an average daily volume of 101,800 shares, the days-to-cover ratio is currently 1.8 days. Approximately 2.9% of the company's shares are short sold. View RA Medical Systems' Current Options Chain.
Who are some of RA Medical Systems' key competitors?
Some companies that are related to RA Medical Systems include Endologix (ELGX), Apollo Endosurgery (APEN), STRATA Skin Sciences (SSKN), Pro-Dex (PDEX), AIT Therapeutics (AITB), BeyondAirInc . (XAIR), Motus GI (MOTS), Nephros (NEPHD), Invo Bioscience (IVOB), SANUWAVE Health (SNWV), Nuvectra (NVTR), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), Arch Therapeutics (ARTH) and Neovasc (NVCN).
What other stocks do shareholders of RA Medical Systems own?
Who are RA Medical Systems' key executives?
RA Medical Systems' management team includes the folowing people:
- Mr. Dean Irwin, CEO, Chief Technology Officer & Chairman of Director (Age 56)
- Mr. Jeffrey Jay Kraws, Pres (Age 55)
- Ms. Melissa Burstein, Exec. VP & Director (Age 43)
- Mr. Richard Heymann, Director of Corp. Strategy & Bus. Devel. (Age 64)
- Mr. Andrew C. Jackson, Chief Financial Officer (Age 50)
When did RA Medical Systems IPO?
(RMED) raised $50 million in an IPO on Thursday, September 27th 2018. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and Cantor acted as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.
How do I buy shares of RA Medical Systems?
Shares of RMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is RA Medical Systems' stock price today?
One share of RMED stock can currently be purchased for approximately $1.36.
How big of a company is RA Medical Systems?
RA Medical Systems has a market capitalization of $17.58 million and generates $6.26 million in revenue each year. The company earns $-30,830,000.00 in net income (profit) each year or ($3.34) on an earnings per share basis. RA Medical Systems employs 95 workers across the globe.View Additional Information About RA Medical Systems.
What is RA Medical Systems' official website?
How can I contact RA Medical Systems?
RA Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company can be reached via phone at 760-804-1648 or via email at [email protected]
MarketBeat Community Rating for RA Medical Systems (NYSE RMED)
MarketBeat's community ratings are surveys of what our community members think about RA Medical Systems and other stocks. Vote "Outperform" if you believe RMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
